Cue Biopharma Inc (CUE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.44-0.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CUE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | 37.7 | 27.5 | 9.3 | 5.5 | 1.2 | 14.9 | 3.2 | 3.5 | 1.1 |
| Operating Expenses & Income | |||||||||
| R&D Expenses | 77.2 | 37.7 | 36.3 | 40.8 | 38.6 | 41.3 | 33.5 | 27.5 | 28.5 |
| Operating Income | (98.7) | (26.6) | (41.5) | (52.1) | (53.2) | (43.7) | (45.0) | (36.8) | (38.7) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | 0.1 | 0.1 | 0.1 | 0.1 | — | — | — | — |
| Other Non-Operating Income / Expenses | (64.9) | 0.5 | 0.8 | 1.4 | 0.2 | 0.0 | 0.5 | 0.5 | 0.5 |
| EBT, Incl. Unusual Items | — | — | — | — | (53.0) | (43.7) | (44.6) | (36.3) | (38.2) |
| Income Tax Expense | — | 0.5 | — | — | 0.0 | 0.5 | 0.2 | 0.4 | 0.8 |
| Net Income | |||||||||
| Net Income | (164.1) | (26.6) | (40.7) | (50.7) | (53.0) | (44.2) | (44.8) | (36.7) | (39.0) |
| Per Share | |||||||||
| Basic EPS | (25.88) | (0.28) | (0.72) | (1.11) | (1.49) | (1.41) | — | — | — |
| Diluted EPS | (25.88) | (0.28) | (0.72) | (1.11) | (1.49) | (1.41) | — | — | — |
| Revenue per Share | 5.94 | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 6.3 | 94.7 | 56.3 | 45.8 | 35.6 | 31.3 | — | — | — |
| Diluted Weighted Avg Shares | 6.3 | 94.7 | 56.3 | 45.8 | 35.6 | 31.3 | — | — | — |
| Supplemental | |||||||||
| EBITDA | — | (25.6) | (41.1) | (51.6) | (52.3) | (42.5) | (44.0) | (36.0) | — |
| EBIT | (98.7) | (26.6) | (41.5) | (52.1) | (53.2) | (43.7) | (45.0) | (36.8) | (38.7) |
| Effective Tax Rate | — | — | — | — | 0.0% | -1.1% | -0.5% | -1.1% | -2.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.